Significantly altered promoter expression in OxPhosi-sensitive and OxPhosi-resistant AML cells after OxPhosi treatment in vivo
| . | OxPhosi-sensitive . | OxPhosi-resistant . | |||||
|---|---|---|---|---|---|---|---|
| Patient No. . | 27 . | 28 . | 29 . | 30 . | 31 . | 32 . | 33 . |
| CCR8 | NC | NC | NC | Up | Up | Up | Up |
| BAI2 | NC | NC | NC | Up | Up | Up | Up |
| LAG3 | NC | NC | NC | Up | Up | NC | Up |
| ATN1 | Down | Down | NC | Up | Up | Up | NC |
| PLXDC1 | NC | NC | NC | Up | Up | Up | Up |
| . | OxPhosi-sensitive . | OxPhosi-resistant . | |||||
|---|---|---|---|---|---|---|---|
| Patient No. . | 27 . | 28 . | 29 . | 30 . | 31 . | 32 . | 33 . |
| CCR8 | NC | NC | NC | Up | Up | Up | Up |
| BAI2 | NC | NC | NC | Up | Up | Up | Up |
| LAG3 | NC | NC | NC | Up | Up | NC | Up |
| ATN1 | Down | Down | NC | Up | Up | Up | NC |
| PLXDC1 | NC | NC | NC | Up | Up | Up | Up |
Down, downregulated by OxPhosi treatment; NC, no significant change with OxPhosi treatment; Up, upregulated by OxPhosi treatment.